Related Experiment Videos
Omapatrilat normalizes renal function curve in spontaneously hypertensive rats
P Morazo1, L A Fortepiani, M Clara Ortíz
1Departamento de Fisiología, Facultad de Medicina, Murcia, Spain. fypruiz@teleline.es
BMC Pharmacology
|October 11, 2001
Summary
Omapatrilat, a vasopeptidase inhibitor, normalized blood pressure in spontaneously hypertensive rats (SHR) without impairing renal sodium excretion. This study demonstrates omapatrilat
Area of Science:
- Cardiovascular Research
- Renal Physiology
- Pharmacology
Background:
- Spontaneously hypertensive rats (SHR) exhibit elevated blood pressure.
- Vasopeptidase inhibitors represent a novel therapeutic class.
- Understanding renal response to antihypertensives is crucial.
Purpose of the Study:
- To analyze the chronic renal response to omapatrilat in SHR.
- To evaluate the impact of omapatrilat on blood pressure and renal function during salt loading.
- To construct chronic renal curves to assess pressure natriuresis relationships.
Main Methods:
- Administered omapatrilat (40 mg/kg/day) orally to SHR and Wistar-Kyoto (WKY) rats for 15 days.
- Utilized a 4-day salt loading protocol (8-fold increase in sodium intake).
- Monitored mean arterial pressure (MAP) and assessed sodium balance.
Main Results:
- Omapatrilat significantly reduced MAP in both SHR and WKY rats under normal sodium intake.
- The antihypertensive effect was more pronounced in SHR, normalizing their MAP.
- Elevated sodium intake did not significantly increase MAP in either group, indicating preserved renal sodium handling.
Conclusions:
- Chronic omapatrilat treatment normalizes blood pressure in SHR.
- Omapatrilat does not adversely affect the renal capacity to excrete sodium loads.
- Omapatrilat resets the pressure natriuresis relationship in SHR to normal levels.